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There is increasing interest in clinical prediction models in psychiatry, which focus on 
developing multivariate algorithms to guide personalized diagnostic or management 
decisions. The main target of these models is usually the prediction of treatment response 
to different antidepressant therapies. This is because the ability to predict response based 
on patients’ personal data may allow clinicians to make individualised treatment decisions, 
and to provide more efficacious or more tolerable medication to a specific patient. Here, we 
systematically search the literature for systematic reviews about treatment prediction in the 
context of existing treatment modalities for adult unipolar depression, until July 2019. 
Treatment effect is defined broadly to include efficacy, safety, tolerability and acceptability 
outcomes. We first focus on the identification of individual predictor variables that may 
predict treatment response, and second, we consider multivariate clinical prediction 
models. Our meta-review included a total of 10 systematic reviews; seven (from 2014-2018) 
focusing on individual predictor variables and three focusing on clinical prediction models. 
These identified a number of sociodemographic, phenomenological, clinical, neuroimaging, 
remote monitoring, genetic and serum marker variables as possible predictor variables for 
treatment response, alongside statistical and machine-learning approaches to clinical 
prediction model development.  Effect sizes for individual predictor variables were generally 
small and clinical prediction models had generally not been validated in external 
populations. We identify the need for rigorous model validation in large external data-sets 
to prove the clinical utility of models. We also discuss potential future avenues in the field of 
personalized psychiatry, particularly the combination of multiple sources of data and the 
potential of the emerging field of artificial intelligence and digital mental health to identify 
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BDNF; Brain-derived neurotrophic factor 
CBASP; Cognitive behavioral analysis system of psychotherapy 
CBT; Cognitive behavioral therapy 
CRP; C-reactive protein 
DOR; Diagnostic odds ratio 
DSM; Diagnostic and Statistical Manual of Mental Disorders 
EEG; Electroencephalography 
HAM-D, HDRS; Hamilton Depression Rating Scale  
ICD; International Classification of Diseases  
IL-6; Interleukin 6 
MADRS; Montgomery–Åsberg Depression Rating Scale 
MDD; Major Depressive Disorder 
NDST; Non-directive supportive therapy  
RCT; Randomised controlled trial  
rTMS; Repetitive transcranial magnetic stimulation 
SMD; Standardised mean difference  
SSRI; Selective serotonin reuptake inhibitor  
TCA; Tricyclic antidepressant  
tDCS; Transcranial direct current stimulation  
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1. INTRODUCTION  
There is an increasing interest into the use of so-called ‘precision’ (or ‘personalized’) 
medicine in psychiatry, particularly to predict treatment effects (Cohen et al, 2018). This has 
led to the recent development of an increasing number of clinical prediction models, a term 
used to describe a multivariate algorithm that utilizes patient-level data in order to make 
individualized clinical predictions (Wessler et al, 2015). It is hoped that clinical prediction 
models may inform improved clinical decisions and offer patients more efficacious, safer or 
better tolerated treatments based on their personal data, especially in the context of digital 
mental health (Shinohara et al., 2019a).   
 
Depression is a psychiatric disorder typically characterised by low mood, reduced energy 
and anhedonia in addition to a number of associated symptoms. Estimates suggest over 300 
million people globally experience depression, making it the single largest factor 
contributing to disability worldwide (Liu et al., 2019). However, depression also exhibits 
heterogeneity. Based on DSM-5 criteria alone, there are 227 unique symptom profiles which 
meet criteria for a diagnosis of Major Depressive Disorder (MDD) (Fried et al., 2015). 
Likewise, depressive episodes may represent manifestations of different conditions, such as 
unipolar depression or bipolar affective disorder. Therefore, depression is commonly 
classified into a number of different categories, based on the severity, nature and type of 
symptoms present as well as their response to treatment (Table 1).  
 
Precision medicine can be particularly relevant to unipolar depression, where a plethora of 
treatment modalities exist with potential effectiveness for any given individual (Table 2). In 




treatments may differ between individuals (Cipriani et al., 2019). In the context of 
pharmacotherapy, a recent analysis of 87 eligible randomized placebo-controlled trials 
identified significantly more variability in response to antidepressant medications than to 
placebo, and this variability differed between different classes of medications (Maslej et al., 
2020). Consequently, there is increasing interest in using clinical prediction models to better 
tailor treatment to each individual patient, based on his/her characteristics, to enhance 
treatment effectiveness, tolerability or acceptability (Tomlinson et al., 2019). This also 
mirrors interest in predicting long-term response from an individual’s initial response in 
order to avoid protracted courses of potentially ineffective or harmful treatments (Hallgren 
et al, 2017).   
 
An array of variables have been hypothesised to be useful in informing clinical prediction 
models in depression. These include sociodemographic, phenomenological, psychological, 
neuroimaging, genetic, immune, endocrine and remote monitoring data (Perlman et al, 
2019). However, the predictive ability of these variables and their reliability across different 
clinical populations is still unclear (Bzdok & Meyer-Lindenberg, 2018). In this paper, we will 
employ a three-fold categorization of predictor variables (Simon & Perlis 2010). We will 
assume that a variable may act as a prognostic factor, a specific predictor of treatment 
response, or as an effect modifier. These terms are explained below: 
• Prognostic factor - A variable is a prognostic factor when it moderates response but 
does not interact with treatment. It affects the outcome in the same way for all 
patients, irrespectively of the received treatment (including placebo).  
• Specific predictor - A variable is a specific predictor when it affects the outcome in 




the way it affects outcome in patients receiving placebo. For example, a specific 
predictor moderates the efficacy of a intervention vs. placebo but does not 
moderate the effect of two different interventions. 
• Effect modifier – A variable is an effect modifier when it moderates response and 
interacts with treatment. This suggests that the relative effects between any two 
treatments (active or placebo) depend on the value of the effect modifier.   
 
We will also include studies that present data on variables that predict within-group 
treatment response. It is not possible to conclude that these variables are specific predictors 
or effect modifiers because they have not been assessed for a differential effect in multiple 
intervention or placebo arms. As it is not possible to assess the true nature of these within-
group predictive variables within a population, we simply provide a description of what can 
be concluded from the current evidence. 
 
All of the categories described above are formative to model development and in this 
review we include them under the broad category of “predictive factors” (Simon & Perlis, 
2018). We include any patient-specific variable which may predict future treatment 
response, including both baseline variables and markers of early response following 
treatment initiation, as either could plausibly inform clinical decisions when deciding to 
initiate, change or stop treatments. Likewise, clinical prediction models have been 
developed using a variety of statistical and machine-learning approaches. The data (‘training 
sets’) that these models are developed from vary in scope, quality and clinical significance. 
Stern and colleagues argued that despite promising results, clinical prediction models have 




(Stern et al, 2018). Additionally, clinical prediction models are derived from a variety of 
different methods and are often evaluated against a variety of different metrics, making 
quantitative analysis difficult. Previous systematic reviews have been limited in scope to 
specific technical approaches used to develop clinical prediction models and therefore may 
not provide a comprehensive overview of the field (Lee et al, 2018).   
 
This meta-review focuses on existing treatments including pharmacological, psychological, 
neuromodulatory and electroconvulsive therapies and aims to summarize the literature on 
the prognostic value of individual variables and clinical prediction models that forecast 
treatment effects in people with unipolar depression. We conceptualise treatment effects 
broadly, including efficacy, safety, tolerability and acceptability. Although there is overlap 
between these terms, safety typically refers to the occurrence of specific adverse events, 
tolerability to the number of people who stop treatment because of adverse events, 
whereas acceptability refers to dropouts from any-cause (Shinohara et al., 2019b). In our 
discussion, we also briefly outline the use of prediction in other disorders in psychiatry, as 
well as in other medical specialties such as oncology, neurology and cardiovascular 
medicine, to illustrate how predictive models may enhance future clinical practice relevant 
to psychiatry in general and unipolar depression in specific. 
 
2. METHODS  
We conducted a meta-review of the English-language literature on the topic of treatment 
response prediction in the context of unipolar depression in adults, considering existing 
systematic reviews and meta-analyses. We followed the Preferred Reporting Items for 




focuses on: i) individual predictor variables and ii) clinical prediction models of treatment 
effects for any treatment intervention in unipolar depression in adults. Our protocol is 
registered with PROSPERO (CRD42019141425). 
 
2.1. Search strategy: 
We searched Ovid MEDLINE, EMBASE and PsycINFO from inception to 15th July 2019, using 
the following keywords/terms: “prediction”, “antidepressants”, “psychological therapy”, 
“psychotherapy”, “electroconvulsive therapy”, “transcranial magnetic stimulation”, “vagal 
nerve stimulation”, “unipolar depression”, “major depressive disorder”. Our complete 
search strategy is detailed in a freely available data repository 
(http://dx.doi.org/10.17632/3v49p2dtnx.1). Our search of electronic databases was 
complemented by a manual search of the reference lists of relevant publications.  
 
2.2 Selection criteria:  
The titles and abstracts of all references were screened for eligibility by three authors (GG, 
AT, AC). Full-texts of potentially eligible references were then retrieved and assessed for 
inclusion. Inclusion criteria was limited to systematic reviews of male and female adults 
(≥18 years) with a primary diagnoses of unipolar depression according to standard 
operationalised criteria such as DSM-III, DSM-III-R, DSM-IV, DSM-5, ICD-10 or Research 
Diagnostic Criteria who received any treatment modality for depression. Reviews of 
individuals with schizophrenia, bipolar disorder and dementia were excluded (studies with 
psychiatric co-morbidities were included only if participants had a primary diagnosis of 
unipolar depression or results were presented separately for unipolar depression). Reviews 




study) as predictor variables were excluded as they were not felt to be relevant to our 
review’s focus. See protocol for further detail.  
 
For the meta-review of individual predictor variables, studies were classified into seven 
groups, guided by their search strategy, presentation of results, critical appraisal and 
quantitative synthesis (Table 3). Our review focuses on the most rigorous systematic 
reviews, classified as level 4 (Table 4), although we also summarise reviews classified as 
level 3 (Table 5). 
 
2.3 Data synthesis: 
Relevant information was extracted from included reviews, including aim(s), intervention(s), 
population, variable(s) of interest, outcome predicted, methodology, types of clinical 
prediction model(s), their evaluation and validation. Data extraction for reviews of clinical 
prediction models mirrored guidelines set out by standardized checklist such as the 
CHARMS checklist, a data extraction tool specficially designed for systematic reviews of 
prediction modelling studies (Moons et al, 2014). We anticipated that, due to the 
heterogeneity of included studies, a quantitative synthesis would not be possible. We 
therefore presented a qualitative synthesis of results from the two areas of focus 
separately; i) individual predictor variables and ii) clinical prediction models.  
 
2.4 Critical appraisal: 
The AMSTAR-2  tool (Shea et al, 2017) is a popular instrument used to critically appraise 
systematic reviews with particular focus on a number of ‘critical domains’; pre-registration 




the appropriateness of meta-analytical methods, the risk of bias from individual studies, the 
consideration of this risk and the assessment of publication bias. The instrument was used 
to critically appraise all the included systematic reviews in this meta-review. 
 
3. RESULTS  
Our search returned 1,869 unique references and we retrieved the full-text of 205 articles. 
118 references were initially deemed to be relevant to individual predictor variables, of 
which 21 were classified as level 3 or level 4 (Figure 1). Seven of these were classified as 
level 4 (including a single, well-defined population or treatment intervention) and are 
discussed in our results (Table 4). The remaining 14 reviews are summarized in Table 5. 
Three reviews concerning clinical prediction models were included (Table 6).   
 
3.1 Individual predictor variables: 
Of the seven included reviews, two focused on studies comparing cognitive behavioral 
therapy (CBT) with pharmacotherapy (Cuijpers et al, 2014; Cuijpers et al, 2017a), two 
focused on studies including all antidepressant medications (Polyakova et al, 2015; Wagner 
et al, 2017), one focused on two antidepressants, venlafaxine and sertraline (Gibiino et al, 
2014), one focused on transcranial direct current stimulation in isolation or in addition to 
pharmacotherapy (Shiozawa et al, 2014) and one focused on cognitive-behavioral analysis 
system of psychotherapy (CBASP), pharmacotherapy or a combination of both (Furukawa et 
al, 2018).  
 




Variables of interest included demographic variables such as age (3 reviews), gender (3), 
childhood maltreatment (2), marital status (2), social adjustment (1), job (1), education level 
(1), clinical variables such as baseline depression severity (3), age of onset (2), duration of 
episode (2), subtype of depression (2), number of previous episodes (1), prior treatments 
received (1), treatment resistance (1), baseline anxiety severity (1), family history (1), early 
clinical improvement following treatment initiation (1) and biochemical variables such as 
serum and plasma levels of brain-derived neurotrophic factor (BDNF) levels following 
treatment initiation (1).  
 
3.1.2 Methods 
A variety of methods were used to assess possible relationships between predictor variables 
and outcomes. Two studies (Cuijpers et al, 2014; Cuijpers et al, 2017a) used a one-step 
individual patient data meta-regression to identify differential response to treatments, 
differential response to treatment and placebo, or response to individual treatments for a 
single predictor variable of interest (gender and subtype of depression, respectively). Both 
reviews reported estimated coefficients to present the relationship between predictor 
variables and treatment outcomes, adjusted for other covariates which might otherwise act 
as confounding factors. One study  reported coefficients from a meta-regression analysis 
(Gibiino et al, 2014; Shiozawa et al, 2014). In contrast, Polyakova et al, 2015 assessed the 
effect of a single predictor variable (BDNF change) and considered treatment responders, 
remitters and non-responders as categorical groups, comparing BDNF change in each group. 
This review included studies which attempted to predict treatment response at end-point 
(week 6) from changes in BDNF levels at day seven; therefore BDNF levels were included as 




reviews above (Dreimüller et al, 2012). Similarly, Wagner and colleagues (2017) assessed 
the role of a single predictor variable (early improvement) and reported outcomes including 
sensitivity, specificity and odds ratios of responding to treatment for categorical groups of 
early improvers and non-improvers.  
 
3.1.3 Outcomes 
All seven reviews reported outcome data related to efficacy, generally reporting on 
treatment response or remission as defined using a standardized depression scale including 
the Hamilton Depression Rating Scale (HAM-D), Beck’s Depression Inventory (BDI), and the 
Montgomery–Åsberg Depression Rating Scale (MADRS). One review also reported on 
deterioration of depression symptoms (Furukawa et al, 2018). Only one review (Furukawa et 
al, 2018) considered acceptability (dropout rate) as an outcome, while none were designed 
to identify predictors of tolerability or the development of specific adverse events.  
 
With regards to efficacy, Cuijpers et al, 2014, 2017a found no evidence that either subtype 
of depression (melancholia, atypical) or gender were associated with treatment response to 
CBT or pharmacotherapy as an effect modifier, specific predictor or within-group predictive 
variable. Gibiino et al, 2014 found that female gender (standardized mean difference (SMD) 
between groups: 1.43, p=0.007) was a within-group predictive vairable of response to 
venlafaxine, as were shorter duration of illness (SMD 0.98, p=0.001) and Caucasian ethnicity 
(SMD 2.57, p=0.0212), but there was weaker evidence of an association at week 6 (SMD 
2.21, p=0.125). There was no evidence that baseline depression severity was associated 
with venlafaxine response. There was very weak evidence of an association with recurrent 




sertraline response. Furukawa et al, 2018 found evidence that baseline depression and 
anxiety severity and use of prior medications were effect modifiers for CBASP, 
pharmacotherapy or combination therapy (predicted relative treatment effects ranged 
between -3.9 and 9.4 on HAM-D scores in sub-groups defined by these three variables). No 
variables were found to be predictors of deterioration in this analysis. There was little 
evidence that baseline depression severity can be used to predict antidepressant response 
or remission in the Wagner et al, 2017 review (explained variance in odds ratios: 0.6%, 
p=0.744 and 8.1%, p=0.285 respectively).  
 
Polyakova and colleagues (2015) identified that serum, but not plasma, BDNF increased 
more in responders (Cohen’s d=1.33, 95% CI 0.69–1.97) and remitters (d=0.85, 95% CI 0.39–
1.29) following antidepressant medication including Selective Serotonin Reuptake Inhibitors 
(SSRIs), Selective Noradrenergic Reuptake Inhibitors, Tricylcic Antidepressants (TCAs) and 
atypical antidepressants compared to non-responders, while Wagner et al, 2017 found that 
patients with early improvement were more likely to achieve response (pooled OR 8.37, 
95% CI: 6.97; 10.05) or remission (pooled OR 6.38, CI: 5.07; 8.02) compared to those 
without early improvement. Cohen’s d is an estimate of effect size, and is often interpreted 
as small where effect size is >0.2, medium where effect size is >0.5 or large where effect size 
>0.8 (Cohen, 1988). Confidence intervals quantify the uncertainty estimated effects, by 
providing  a range of values within which the true effect size is expected to lie 95% of the 
times. In the context of transcranial direct current stimulation, one study found no evidence 
of association between age, gender, baseline depression severity or treatment-resistance 





With regards to acceptability, Furukawa et al, 2018 found evidence that age and subtype of 
depression modify the effect of CBASP compared to combination of CBASP and 
pharmacotherapy, although it is difficult to disentangle the effects of individual covariates 
as this study modelled interactions between different combinations of predictor variables 
rather than considering each variable as a predictive factor in isolation.  
 
3.1.4 Critical appraisal 
AMSTAR-2 assessements are summarised in Table 4, with full details for each study 
available in a data repository (http://dx.doi.org/10.17632/3v49p2dtnx.1). All seven reviews 
contained two or more flaws in critical domains and therefore were considered to have 
“critically low” quality. Common areas of weakness included a lack of explicit statement 
detailing that methods were established prior to review commencement, failure to provide 
a list of excluded studies and a lack of consideration of risk of bias when interpreting results.   
 
3.2 Clinical Prediction Models:  
Our search returned three reviews meeting our inclusion criteria for assessment of clinical 
prediction models (Table 6). Bos et al, 2015 presented a broad review on the role of 
experience sampling and ecological momentary assessment in prescribing of psychotropic 
medications in MDD. The authors identified one study involving a sample of 49 patients 
receiving the tricyclic antidepressant imipramine, which found a clinical prediction model 
combining measures of early change in HDRS with early measures of positive affect 
(measured by experience-sampling) improved prediction of response and remission 
compared to single variables alone (Geschwind et al, 2011). The model accounted for 28 




the clinical prediction model was developed using information of relatively few patients and 
also given that it was not validated in an external sample, its clinical usefulness remains 
questionable.  
 
Lee et al, 2018 presented a review of clinical prediction models in the context of depression. 
Although criteria included both bipolar and unipolar depression, components of the 
qualitative and quantitative syntheses presented results exclusively from participants with 
unipolar depression. Twenty-six studies were included, two of which featured both bipolar 
and unipolar depression, with the remainder featuring solely unipolar depression. Clinical 
prediction models predicted a range of proxy-markers of treatment response, including 
patient- or observer-rated symptom scales, frequency of hospital admission or suicidal 
ideation. The majority (92%) of models used supervised-learning algorithms, including 
logistic regression, support vector machines, decision trees, linear discriminant analysis, 
gradient boosting machines, random forest algorithm and mixture of factor analysis (Iniesta 
et al., 2016, Redlich et al., 2016, Korgaonkar et al., 2015, Al-Kaysi et al., 2017, Chekroud et 
al., 2017, Kautzky et al., 2017, Khodayari-Rostamabad et al., 2013). Unsupervised 
approaches included neural networks (Serretti et al., 2007).  
 
Candidate predictors in clinical prediction models were most commonly neuroimaging 
(defined as Magnetic Resonance Imaging (MRI), functional Magnetic Resonance Imaging 
(fMRI) or Electroencephalography (EEG), phenomenological (defined as baseline symptom 
scores, functioning, number of previous depressive episodes and sociodemographic 
variables including employment, education, household income). Two studies focused 




three studies used phenomenological predictors in combination with genetic or 
neuroimaging predictors (Guilloux et al., 2015, Kautzky et al., 2015, Dysdale et al., 2017). 
Studies generally evaluated their models using classification accuracy. All studies reported a 
percentage rate of correct classification, apart from one study (Iniesta et al., 2016) that 
reported the area under the receiver-operator characteristic curve, a commonly used 
measure in medical decision-making to determine how well a model or tool distinguishes 
between groups (Hoo et al., 2017). Sensitivity and specificity were also commonly reported. 
Importantly, only four of 20 studies evaluated models in an external dataset and one study 
evaluated performance with hold-out validation. Quantitative pooling of phenomenological 
and combined prediction models reported classification accuracy of 0.76 (CI: 0.63; 0.87) and 
0.93 (CI: 0.86;0.97) respectively, but pooled classification accuracy of neuroimaging and 
genetic prediction models were presented separately for participants with bipolar and 
unipolar illness. The authors note that application of commonly-used methods (Egger’s test 
and funnel plot asymmetry) provided some indication of small study effects and publication 
bias in their included studies, suggesting that smaller studies gave larger estimates. This 
might be the case for example when studies with negative results were less likely to be 
published than those with positive findings.   
 
Five studies included in the review by Lee et al, 2018 compared results from machine-
learning approaches with conventional statistical analyses of the same dataset (Bailey et al., 
2018, Liu et al., 2012, Serretti et al., 2004, Serretti et al., 2007, van Waarde et al., 2014,). 
Three neuroimaging studies failed to identify baseline predictors of treatment response with 
univariate analysis while the machine-learning algorithms predicted response with a 




et al., 2014,). However, multiple regression analysis in another study did identify clinical and 
demographic predictor variables such as the number of previous depressive episodes, age of 
onset and the duration of the current episode, consistent with machine-learning 
methodology (Serretti et al., 2007).  
 
Finally, Rosenblat et al, 2017 presented another approach to clinical prediction models in a 
review focusing on whether pharmacogenomic clinical prediction models improved 
treatment response. The review included five studies from three separate commercial 
pharmacogenomic models featuring a variety of candidate predictor genetic variants. Due 
to these tools’ commercial nature and study of design, the exact outcome predicted, or 
advice outputted, by each tool is poorly reported but guided treatment selection and 
dosing. However, the reviewers focused on the clinical validation of these tools, assessing 
changes in depression severity, response or remission rates among participants whose 
clinician used the tool. While no tolerability or acceptability data were reported in the 
review, the candidate predictor variables included genes supposedly associated with 
adverse reactions, alongside those associated with treatment efficacy and drug metabolism. 
The review included four controlled trials (two randomized and two non-randomized) and 
one naturalistic study lacking a control group (Hall-Flavin et al., 2012, Hall-Flavin et al., 2013, 
Winner et al., 2013, Singh, 2015, Brennan et al., 2015). Two open-label non-randomized 
trials showed an improvement in response and remission rates when using a 
pharmacogenomic tool, however this result was not replicated for the same tool in a 
randomized-control blinded study (Hall-Flavin et al., 2012, Hall-Flavin et al., 2013, Winner et 
al., 2013). A randomized-controlled double-blinded trial of a different tool did show 




interpreting results due to the study funding arising from the developers of the tool (Singh, 
2015). Results were not independently replicated. The naturalistic study suggested 
improvement compared to baseline but lacked a control group for comparison. 
 
In terms of critical appraisal using AMSTAR-2, all three reviews contained two or more flaws 
in critical domains and therefore were considered to have “critically low” quality (Table 6). 
Common areas of weakness were a lack of explicit statement detailing that methods were 
established prior to review commencement, failure to provide a list of excluded studies and 
a lack of consideration of risk of bias when discussing results.   
 
4. DISCUSSION 
4.1 Individual predictor variables: 
This meta-review identified seven reviews meeting our inclusion criteria for individual 
predictor variables. No single variable was found to consistently predict treatment response 
across multiple reviews. It is possible that this finding represents specificity of individual 
predictive variables to specific treatments (Simon & Perlis 2010). Alternatively, due to the 
high number of retrospective analyses performed for a variety of candidate predictor 
variables, it is also possible that some of the studies’ findings arose from chance (Head et al, 
2015). However, the lack of consistent statistically significant findings across different 
studies does not in itself demonstrate disagreement, as it may simply result from meta-
analyses being under-powered to detect the effects of the explored variables to the 
outcome of interest. Also of particular note are cases where the effects estimated for the 
individual predictor factors had small effect sizes. In such cases, the clinical significance of 




age predicted worse outcome when considered as a continuous variable, but the difference 
in outcome associated with older age was so small that it would unlikely be recognized by 
patients or clinicians without the use of numerical rating scale.  
 
All seven included reviews focused on efficacy, with only one review presenting 
acceptability data (Furukawa, et al., 2018). Broadening our search to include level 3 reviews 
(Table 5), identified one further review of tolerability in the context of amitriptyline (Chen et 
al, 2018) and two further reviews of acceptability in the context of psychotherapy (Karyotaki 
et al, 2015, Cooper et al, 2015). This may represent a relatively unexplored area in this field, 
especially given the variety of potentially under-utilized treatments licensed for unipolar 
depression (Table 2) which exhibit potentially clinically relevant differerences in terms of 
efficacy and acceptability (Cipriani et al, 2018). Other medical specialties, such as 
cardiovascular medicine, have struggled to predict adverse effects due to their relatively low 
frequency in clinical trial data (van der Leeuw et al, 2014), although there is limited 
precedent for doing so, with the example of natalizumab (Tysabri) in multiple sclerosis. In 
this case, data from postmarketing sources, clinical studies, and a national registry identified 
antibodies which predicted occurrence of a rare but potentially life-threatening progressive 
multifocal leukoencephalopathy (PML) following treatment with the drug (Bloomgren et al, 
2012).  
 
Only three of the seven reviews of individual predictor variables listed in Table 4 were 
designed to identify variables acting as effect modifiers, with gender, subtype of depression 
and clinical factors (such as age of onset, number of precious depressive episodes) 




reviews reported on specific predictors, by assessing variables which may predict 
differential response in the intervention arm compared to a placebo arm. All seven reviews 
assessed for within-group predictive variables, whereby the predictive efficacy of variables 
were not compared with a second active intervention or placebo arm. Variables investigated 
in such a way, including age, gender, ethnicity and duration of depressive episode, may 
therefore represent prognostic factors, specific predictors or effect modifiers (Gibiino et al, 
2014). Furthermore, we found that these terms were used inconsistently, with some studies 
reporting on “moderator” variables without an appropriate study design to distinguish 
effect modifiers from prognostic factors (Gibiino et al, 2014). For example, while female 
gender was shown to be associated with response to venlafaxine and there was no evidence 
of an association with response to sertraline, this cannot be considered evidence of effect 
modification. For this, a formal statistical analysis would be required (Cuijpers et al, 2014, 
2017a and Furukawa et al, 2018). Indeed, in this example it is possible that gender may be a 
generic prognostic factor and that certain samples were underpowered to detect an 
association, rather than there being a differential effect.  
 
Likewise, in our broader search (Table 5) we identified a number of reviews assessing 
whether variables predicted response in a pooled grouping of multiple treatment 
interventions or placebo. Such analyses are not adequate to elucidate prognostic factor, 
specific predictor or within-group effects since they do not clarify whether variables affect 
response differentially in each treatment arm or placebo as they only present the pooled 
effect size for all component treatment arms or placebo. Analyses containing hetergenous 
treatment interventions not assessed independently are therefore of limited value and are 




effect modifiers, specific predictors and prognostic factors in order to isolate the individual 
relationships between predictor variables and specific treatments rather than more generic 
predictors of outcome has been discussed in the literature previously (Simon and Perlis, 
2010).  
 
There was also heterogeneity in how treatment response was conceived and reviewed 
across different studies. Approaches included categorical variables (response defined as an 
>50% improvement symptoms) or continuous variables (symptom severity change pre- and 
post-intervention using a variety of different rating scales), measured at different time-
points and using different cut-offs. Heterogeneity also existed in the individual predictor 
variables themselves. For serum and plasma markers such as BDNF, samples were drawn at 
different time-points between studies (Polyakova et al, 2015). In particular, the clinical 
utility of the results presented in that review may be questionable due to the heterogeneity 
of time-points where treatment response and BDNF levels were measured, since BDNF can 
only be used as a predictor of future response if it is measured significantly in advance of 
clinical response measurements. Heterogeneity in study population and treatment setting 
also exist, raising questions about the specific contexts in which individual predictor 
variables and models are valid.  
 
4.2 Clinical prediction models: 
This meta-review identified three reviews of clinical prediction models (Bos et al., 2015, Lee 
et al., 2018, Rosenblat et al., 2017). The clinical prediction models we identified were 
generally poorly validated, and commonly not evaluated on a separate data-set to that 




validated, the test data was often derived from clinical trial settings with similar 
methodology and populations, raising questions about its external validity. The importance 
of internal-external and external validation has been discussed in the literature and is 
important to avoid over-fitting and to improve external validity (Steyerberg and Harrell, 
2016). Therefore, caution should be advised when interpreting results for clinical prediction 
models which haven’t been properly validated.  
 
The lack of external validation is compounded by the need of large datasets to develop 
clinical prediction models. There is evidence that training-sample size is the most robust 
predictor of model performance (Popovici et al, 2010). Therefore, while it is possible to split 
data-sets into training, cross-validation and test sets in order to better evaluate and validate 
models, doing so reduces the sample size which the model is built from, potentially 
compromising its performance. A compromise must often be reached between optimising 
model performance and rigorous validation, especially given that data-set size is already a 
major limitation in precision psychiatry. Indeed, Cuijpers et al, 2012 estimated that in order 
to perform sufficiently powered analyses of individual predictor variables predicting 
pharmacotherapy or psychotherapy response, another 254 studies would have to be 
conducted. 
 
Another limitation of clinical prediction model development is that they do not neccessarily 
inform our understanding of which candidate predictor variables are significant. For 
instance, clinical prediction model development using machine-learning methods such as 
neural networks do not provide individual coefficients for each variable inputted into the 




that one cannot identify the effect of a single covariate to the outcome. Meanwhile 
commercially developed models often do not share the weight assigned to each predictor 
variable in model development. These factors limit our understanding of which candidate 
predictor variables deserve further research interest. This is especially important, given that 
in oncology the selection of candidate predictor variables and data inputted has been 
shown to be a more significant determiner of model performance than the type of 
algorithm used (Jang et al, 2014).  
 
The vast majority of prediction models identified in our meta-review focused on individual 
predictors of just one domain, such as genetic, neuroimaging, demographic or clinical data. 
This raises the difficulty of how to combine prediction models from different domains to 
make more accurate predictions. While an ensemble method using stacking may prove 
useful in combining the predictions of a number of separate prediction models into one, our 
meta-review did not identify any examples of this within the context of unipolar depression 
(Wan et al, 2014). Therefore, in depression, a significant challenge exists in standardizing 
and combining predictor variables of different domains to predict treatment response, 
compared to other specialties such as oncology where pathology is thought to arise 
primarily from genetics (Kelloff and Sigman, 2012).  
 
Finally, similarly to reviews of individual predictor variables, we found that significant 
heterogeneity exists in reviews of clinical prediction models. Alongside heterogeneity in the 
definitions of treatment response and candidate predictor variables, there is heterogeneity 
in the specific context in which a clinical prediction model is valid in. For instance, it is 




failed interventions would fail to accurately predict response to the same drug in the 
context of a new presentation of unipolar depression, or vice versa. This consideration 
emphasises the importance of rigorous model validation in different populations and clinical 
contexts.  
 
All included reviews of individual predictor variables and clinical prediction models were 
deemed to be “critically low” according to the AMSTAR-2 instrument, which is the label 
given to reviews with flaws in at least two critical domains and indicative that reviews 
“should not be relied on to provide an accurate and comprehensive summary of the 
available studies” (Shea et al., 2017). However, it is worth noting that this was often the 
result of not providing a list of excluded studies, which no review did, or not explicitly 
referencing a pre-registered protocol in the article, which only one review did. While these 
criteria represent good practice they are not necessarily evidence that the reviews 
contained bias or were of poor quality. Furthermore, the suitability of the AMSTAR-2 tool 
for some of our included studies could be questioned. Although we felt it is important to 
systematically use a single tool to standardize quality assessment across included reviews, it 
can be argued that AMSTAR-2 does not comprehensively capture all the quality issues 
relevant to each review, and may assess aspects not relevant to some reviews. For instance, 
reviews developing a model (such as Furukawa et al, 2018) might be better assessed by the 
CHARMS checklist, a tool specifically designed for critical appraisal of prediction modelling 
studies (Moons et al, 2014). Furthermore, although a review might be classified as high 
quality, the included studies within that review may be of low quality and therefore review 
quality alone may present a deceiving impression of the overall quality of evidence. In 




results when interpreting their results, raising the possibility that meta-analytic findings may 
conceal biases present in individual component studies.   
 
4.3 Limitations: 
Although our meta-review is wide-ranging in its scope, it exhibits limitations. Our focus on 
treatment response and remission meant that it was not possible to include reviews 
focusing on prediction of relapse following treatment cessation. Most of our included 
reviews measure treatment response within eight weeks of commencing an intervention, a 
relatively short time in the context of unipolar depression (Penninx, 2011). However, an 
equally relevant question is which variables predict relapse or durability of response 
following the cessation of an intervention and how we might design clinical prediction 
models to guide clinical decisions to discontinue treatments (Berwian et al, 2017, Kedzior et 
al, 2015). These reviews are not discussed in detail here but are worthy of consideration due 
to the known chronicity of unipolar depression.  
 
Another limitation of our meta-review is our focus on the most rigorous reviews featuring a 
single, well-defined population or treatment intervention. This may compromise external 
validity, given that the well-defined populations of our included reviews may be dissimilar to 
the wider clinical population. However, this approach was necessary due to the 
heterogeneity of the studies, the methodological rigour of our meta-review and the need to 
clarify the effects of candidate predictor variables. Nonetheless, this concern emphasises 
the importance of proper validation of clinical prediction models in external samples prior 





Finally, this meta-review is limited in the clinical prediction models it identified. It is likely 
that recent clinical prediction models have been published that have not yet been identified 
by systematic reviews and were therefore missed by our literature search. Likewise, clinical 
prediction models may be derived from meta-analysis, such as the Furukawa et al, 2018 
review, which was included in our review of individual predictor variables since it focused 
on relative effectiveness research rather than performance of multiple clinical prediction 
models. While an updated search of primary studies would likely be fruitful in identifying 
further clinical prediction models, it was deemed to be beyond the scope of this                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
review. Rather, our meta-review presents a broader overview of the synthesized literature 
on individual predictor variables and clinical prediction models in unipolar depression.  
 
4.4. Recommendations for future research  
Our findings highlight encouraging efforts towards the prediction of treatment response in 
unipolar depression, in-keeping with the wider interest of applying precision medicine 
methods in psychiatry more generally (Cipriani and Tomlinson, 2019). Our meta-review 
leads us to the following recommendations for future research. 
 
First, we believe the field would benefit from more consistent terminology when 
characterising predictor variables. Here, we use the terms “prognostic factor,” “specific 
predictor” and “effect modifier” to distinguish types of predictor variables, although 
heterogeneity exists in the literature (Simon & Perlis 2010). Similarly, we believe the field 
may benefit from the use of more consistent and clinically meaningful definitions of 




underexplored areas worthy of more structured and standardised investigation that can 
take into account preferences and values of end users (Kernot et al., 2019).  
 
Second, it is noteworthy that the majority of data in our included reviews come from 
randomized-controlled trials. Combining data from other sources, such as observational 
studies and “real-world” clinical data, may aid the identification and development of new 
and possibly stronger candidate variables associated with treatment outcomes and 
prediction models (Tomlinson et al., 2019). If these variables exhibit true effects, we would 
expect findings from randomized study populations to be replicated in large observational 
clinical dataset. Obtaining information from multiple sources would not only provide 
opportunity to optimise model performance and identify further predictor variables, but to 
also thoroughly assess the clinical utility of models and elucidate the specific clinical 
contexts and populations in which they are valid (Vaci et al., 2020). A recent study in 
cardiology highlighted that differences between the population in which prognostic models 
are developed and the populations in which models are tested represents a key 
determinant of model validity (Iwakami et al., 2020). We therefore emphasise the pressing 
need to undertake external validation of clinical prediction models to thoroughly assess 
their performance, clinical utility and to guide their appropriate clinical application.  
 
Other specialties may inform methods to increase access to large data-sets. Oncology has 
benefitted from public repositories of genomic data in its development of targeted 
therapies, while neurology has benefitted from international patient databases when 
developing personalized therapies for multiple sclerosis (Azuaje, 2017, Kalincik et al, 2017). 




identify predictive response biomarkers (Kelloff and Sigman, 2012). Meanwhile networks 
have been designed based on similarities in genomics and drug structures to predict drug 
response, methods which may prove useful in overcoming limited data (Zhang et al, 2015). 
However, it is worth noting that while cancer may be understood as a “genetic disease” 
(Kelloff and Sigman, 2012 ), the same may not be true of psychiatric disorders where a more 
diverse array of predictor variables are likely to contribute to the treatment response 
(Gómez-Carrillo, 2018). Consequently, while personalized therapies in oncology benefitted 
from methods such as co-clinical trials with mouse models, such approaches may not prove 
as successful in psychiatry (Huang et al, 2014).  
 
One particularly exciting area is digital mental health. The emerging field of digital 
phenotyping offers a wealth of behavioral data which is both cost-effective and practical to 
collect (Torous et al, 2018). Although our meta-review identified just one example of a 
prediction model using remote monitoring featuring active data collection (Bos et al, 2015), 
the role of passive data collection not requiring continuous active patient engagement may 
provide abundant clinically relevant data to inform future prediction models (Gillett & 
Saunders, 2019). Such data may prove useful in implementing measurement-based-care, in 
which a patient’s response to a treatment could inform further predictions on a continuous 
basis (Lewis et al, 2019). Our meta-review identified one example of using early 
improvement (Wagner et al, 2017) as a predictor of future response, although this was 
based on established standard symptom rating scales (HAM-D or MADRS) rather than 
remotely collected data. If properly validated, the emergence of clinically-relevant digital 
data may therefore identify new candidate predictor variables and allow clinical prediction 




identification of standardised digital metrics as candidate variables in the prediction of 
treatment effects.  
 
4.5 Conclusions: 
To conclude, this review summarized the evidence on a number of predictive factors for 
treatment response in adult unipolar depression and identified interest in an array of 
predictor variables, especially in the context of efficacy. We found that clinical prediction 
models had generally not been validated in external populations and discuss potential 
future avenues in the field, particularly the need for rigorous external validation, the 
combination of multiple sources of data and the emerging field of digital mental health. 
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Table 1
Summary of classifications of depression.
Type Description Diagnostic criteriaa Typical treatment recommendation
Depressive episode A period lasting at least two weeks, typically
characterised by low mood, reduced energy and
loss of interest or pleasure in normally enjoyable
activities. Associated with impairment in social or
occupational function.
Typically, sub-categorised by severity
(determined by type, severity and number of
individual symptoms).
Mild: At least two core symptoms & two
additional symptoms.
Core symptoms: Low mood, anhedonia,
fatiguability.
Additional symptoms: Reduced concentration,
reduced self-esteem, ideas of guilt and
unworthiness, hopelessness, ideas of self-harm
or suicide, disturbed sleep, changes to appetite.
Psychosocial interventions generally preferred to
pharmacological interventions due to risk-benefit
ratio (Cuijpers et al., 2020).
Moderate: At least two core symptoms & three
additional symptoms.
Pharmacological treatment, typically a
selective-serotonin reuptake inhibitor (SSRI) due
to tolerability in addition to psychosocial
intervention (Cipriani et al., 2018). Patients who
fail to respond should be switched to a 2nd
antidepressant medication (Cowen & Anderson,
2015).
Severe: All three core symptoms & four
additional symptoms.
As (above) for moderate depression.
Recurrent unipolar
depression
A diagnosis given to individuals who have
experienced two distinct depressive episodes.
Patient should have experienced two distinct
depressive episodes separated by several
months without significant mood disturbances.
In addition to treatment for a depressive episode,
antidepressant medications are often continued
for relapse prevention, although the optimal
treatment duration is unclear (Glue, Donovan,
Kolluri, & Emir, 2010).
Bipolar depression A depressive episode seen in the context of a
bipolar disorder illness, where patients
experience mania, hypomania or mixed affective
episodes in addition to depressive episodes.
As well as meeting the criteria for a depressive
episode, patients should have at least one
hypomanic, manic or mixed affective episode in
the past.
If using lithium or a mood-stabiliser, dosing
should be optimised. Antipsychotics (with or
without) SSRI may be offered, or alternatively an
anticonvulsant, however good evidence is scarce
(Vázquez et al., 2014).
Dysthymia Chronic lowmood experienced by patients where
symptoms do not meet the criteria due to
symptom severity or duration. Generally,
symptoms are chronic but associated with less
functional impairment than a typical depressive
episode. Cyclothymia describes a similar
condition which involves mild elation episodes as
well as low mood episodes.
Described as very long-standing depression of
mood which is never (or very rarely) enough to
fill the criteria for recurrent depressive disorder.
Evidence-base similar to mild depression;
psychosocial interventions are generally
preferred.
Atypical depression A debated subgroup of depression, with features
that may include; mood reactivity to positive
events, increased appetite and sleep, pronounced
anxiety and heaviness of limbs.
Classified under “other depressive episodes” In
ICD-10.
“With atypical features” is a specifier in DSM-5.
Historically it was believed atypical depression
responded preferably to Monoamine Oxidase
Inhibitors (MAOIs), however there is no strong
evidence to support this (Łojko & Rybakowski,






A debated subgroup of depression, where
anhedonia and lack of mood reactivity
predominate alongside biological symptoms;
diurnal variation in mood (worse in morning),
early-morning waking, psychomotor agitation or
retardation, weight loss and guilt.
Known as “somatic syndrome” in ICD-10, usually
requiring four somatic symptoms to be present.
“With melancholic features” is a specifier in
DSM-5
No strong evidence to treat melancholic
depression differently to standard treatment for
depressive episodes (Łojko & Rybakowski, 2017).
Psychotic
depression
Severe depressive episodes with psychotic
symptoms. May feature delusions, hallucinations,
or depressive stupor.
As well as meeting criteria for a severe
depressive episode, with delusions,
hallucinations or depressive stupor also present.
Antidepressant in combination with an
antipsychotic thought to be most effective
(Cowen & Anderson, 2015).
Treatment-resistant
depression
A term used to describe depression that fails to
respond to standard treatment, typically defined
as two sequential antidepressant medication
trials.
Not defined in diagnostic manuals (DSM-5 or
ICD-10). Research criteria usually defines
treatment-resistance as a failure to respond to
two or more antidepressant medications
sequentially at adequate dose and duration.
Debates persist around defining response and
adequacy of dosing and duration (Fornaro &
Giosuè, 2010).
Combination (2 or more antidepressant
medications) or augmentation (antidepressant
with an atypical antipsychotic or lithium) is
recommended. Augmentation with atypical
antipsychotic has strongest evidence base
(Cowen & Anderson, 2015).
a ICD-10 classifications are used preferentially, although DSM-5 classifications are also described where necessary.
Table 2
Summary of treatment modalities for unipolar depression.




Commonly used medications include citalopram, escitalopram,
fluoxetine, sertraline, paroxetine.
Medications from all classes shown to be more effective than
placebo. Small relative differences between individual
medications exist for both efficacy and acceptability although
overall there are few differences between individual










Commonly used medications include amitriptyline,
nortriptyline, imipramine and clomipramine.
Monoamine oxidase
inhibitors (MOAIs)




Medications not well characterised by other groupings.
Commonly used medications include vortioxetine, mirtazapine,
bupropion, trazodone and agomelatine
Rapid-acting
antidepressants
Recent interest into using esketamine for rapid-acting treatment,
in combination with established antidepressant medication.
Esketamine recently approved by U.S. Food and Drug
Administration (FDA)
A small number of randomised controlled trials suggest the
possibility of increased response compared to placebo, but no
difference in remission demonstrated (Jauhar & Morrison, 2019).
Psychologicala Cognitive-behavioral
therapy (CBT)
Focus on dysfunctional beliefs and their impact on behaviour.
Aim is to restructure these beliefs.
All the listed psychological therapies have been shown to be
effective in treating depression, with comparable effectiveness




Focus is on encouraging regular and routine activities, which
may be pleasant or functional in nature.
Interpersonal
psychotherapy
Focus is on interpersonal issues in depression.
Problem-solving
psychotherapy
Focus is on identifying problems, formulating solutions, acting
upon them and reviewing outcomes.
Non-directive
counselling
Unstructured therapy focused on offering empathy to patients
sharing their experiences and emotions.
Psychodynamic
psychotherapy




Used in addition to pharmacotherapy in some cases of
treatment-resistant depression.
Meta-analysis evidence that ECT is more effective than simulated




Electrode implanted and attached to vagus nerve to deliver
electrical impulses.
No good evidence that vagal nerve superior to sham in




Uses a magnetic field to generate electrical current in specific
cortical regions.
Evidence for moderate effect in favour of TMS compared to
sham, although there is significant heterogeneity between




Uses scalp electrodes to deliver electrical current to specific
cortical regions.
Robust efficacy has not been consistently demonstrated and
heterogeneity exists between studies (Borrione, Moffa, Martin,
Loo, & Brunoni, 2018)
a This selection has been guided by previous reviews in the literature (Cuijpers et al., 2020) and summarises the main forms of psychological interventions.
Table 3






















2a ✓ ✓ ✓
2b ✓ ✓ ✓
2(a + b) ✓ ✓ ✓ ✓
3 ✓ ✓ ✓ ✓ ✓
4 ✓ ✓ ✓ ✓ ✓ ✓
Table 4




















Searched for RCTs comparing CBT vs
pharmacotherapy in individuals with
depression where HAM-D-17 was
reported.
One-step individual-patient-data
meta-analysis mixed effects model used
to assess association between gender &
treatment response (HAM-D-17). Model
adjusted for age, minority status, marital
status, education, trial characteristics &
quality.
Adults with depression
receiving CBT (individual or
group), pharmacotherapy
(SSRI, TCA or other) or placebo.
1 study included individuals
with dysthymia. 1 study
focused on individuals with
multiple sclerosis, one focused
exclusively on women.
n = 14 studies.
1766 participants.
Effect modifier: No strong evidence of gender being an effect
modifier of CBT vs pharmacotherapy (adjusted coefficient 0.72, p
0.47).
Specific predictor: No strong evidence of gender being a specific
predictor for CBT or pharmacotherapy outcome (CBT: 0.01, p 1.00,
pharmacotherapy: −0.54, p 0.68).
Within-group predictive variable: No strong evidence of gender
being a predictor of within-group response for CBT or
pharmacotherapy outcome (CBT: −0.48, p 0.54,
pharmacotherapy: −0.85, p 0.20).



















also reported in 3 of
4 studies.
[E]
Searched for RCTs comparing CBT vs
pharmacotherapy in individuals where
depression subtype was measured.
One-step individual-patient-data
meta-analyses mixed effects model used
to assess association between
melancholia/atypical depression &
treatment response (HAM-D-17 or
BDI-II). Performed on intention-to-treat
and completers samples separately.
Model adjusted for gender, minority





placebo. USA & Canada.
n = 4 studies.
805 participants.
Effect modifier: No strong evidence of melancholia being an
effect modifier of CBT vs SSRI outcome (adjusted
coefficient − 0.38, p 0.74).
No strong evidence of atypical being an effect modifier of CBT vs
SSRI outcome (adjusted coefficient − 1.83, p 0.15).
In unadjusted completers sample, results suggest atypical
depression responds better to SSRI (coefficient − 2.71, p 0.048),
although caution advised.
Specific predictor: No strong evidence of melancholia being a
specific predictor for CBT or SSRI outcome (CBT: 1.14, p 0.56, SSRI:
1.30, p 0.46).
No strong evidence of atypical being a specific predictor for CBT or
SSRI outcome (CBT: 0.45, p 0.86, SSRI: −2.48, p 0.24).
Within-group predictive variable: No strong evidence of
melancholia being a predictor of within-group response to CBT or
SSRI outcome (CBT: −0.32, p 0.71, SSRI: −0.01, p 0.99).
No strong evidence of atypical being a predictor of within-group
response to CBT or SSRI outcome (CBT:−0.49, p 0.61, SSRI: 1.33, p
0.13).
Other: Outcome differences between melancholia or atypical
depression patients versus those without were consistently small






































Searched for RCTs of CBASP,
pharmacotherapy or combination in
context of recurrent depressive disorder,
depression, dysthymia in Cochrane
CENTRAL, Pubmed, Scopus & PsycINFO.
Synthesized data using
individual-patient-data meta-analysis
and used penalized regression model to
identify covariates (as effect modifiers or
prognostic factors) for development of
predictive model. First and second-order
combinations of the variables of interest
used in this model.
Adults with persistent
depressive disorder (DSM-5),





n = 3 studies.
1036 participants.
Change in depression severity: Effect modifier: Subgrouping by
baseline HAM-D, baseline anxiety and having received prior
medications associated with a small modifier effect for all three
treatments.
Within-group predictive variable: Baseline anxiety, baseline
HAM-D, prior medication and neglect included in model as
prognostic factors alone or in combination. Generally weak
regression coefficients, baseline HAM-D was the most influential
covariate.
Deterioration: Effect modifier: No strong evidence of effect
modifiers identified.
Within-group predictive variable: Baseline HAM-D, baseline
anxiety, social function, marital status included in model as
prognostic factors alone or in combination. Generally weak
regression coefficients & baseline HAM-D was most influential.
Dropouts: Effect modifier: Age & depression subtype (chronic
MDD) associated with small modifier effect for CBASP vs
combination.
Within-group predictive variable: Baseline HAM-D, age, prior
medication, depression subtype (chronic MDD, dysthymia),
marital status included in model as prognostic factors alone or in
combination. Generally weak regression coefficients, baseline



















to week 6 (and week
8 as a secondary
outcome).
[E]
Searched for RCTs of venlafaxine or
sertraline on Medline, EMBASE and
Cochrane Library.
Meta-regression analysis used to
evaluate potential predictor variables
using random-effects model. Categorised
variables expressed as a percentage of
patients enrolled in each study. Patient
data considered on intention-to-treat
basis.
Adults with diagnosis of Major
Depressive Disorder
(excluding dysthymia)
enrolled in RCT receiving
venlafaxine or sertraline.
n = 59 unique trials for
sertraline
6029 participants
n = 57 unique trials for
venlafaxine
6375 participants
Within-group predictive variable: Female gender was associated
with within-group response to venlafaxine (SMD = 1.43,
p = .007 and p = .004 at weeks 6 and 8).
Age was extremely weakly associated with within-group response
to venlafaxine (SMD = -0.01, p = .040), unlikely to be clinically
significant.
Caucasian ethnicity predicted better within-group response to
venlafaxine at week 8 (SMD = 2.57, p = .0212), but no strong
evidence of predicting response at week 6 (SMD = 2.21,
p = .125).
Duration of episode less than 6 months predicted better
within-group response to venlafaxine (SMD = 0.98, p = .001
and p = .004) and duration over 1 year predicted worse response
to venlafaxine at week 6 (SMD = -1.09, p = .0004).
Baseline severity and recurrent depression were not strongly
associated with within-group response to venlafaxine. No
individual patient clinical or demographic factor was strongly
associated with within-group response to sertraline.















on HDRS or MADRS.
Remission, defined
as scores b7 HDRS,
b8 MADRS.
[E]
Searched for case-control or longitudinal
studies of MDD or BD patients receiving
standardised treatment in which serum
BDNF levels were measured in PubMed,
ISI Web of Science, PsycINFO. Bipolar
disorder was included in review, but
results presented separately and not
discussed here.
Standardised mean difference was
calculated from BDNF measurements.
Subdivided MDD sample into
non-responders, responders, remitters.
Random-effects meta-analysis used to
assess association between BDNF &
treatment response.
Adults with a diagnosis of
Major Depressive Disorder
receiving pharmacotherapy in
a case-control or longitudinal
therapy study, excluding




therapy or psychotherapy were
excluded.
Total: n = 48 studies (MDD)
3365 participants (MDD)
Relevant to prediction of
treatment response: n = 21
studies
553 patients
Within-group predictive variable: Serum BDNF levels increased
following treatment initiation for treatment responders
(d = 1.33, 95% CI 0.69–1.97) and treatment remitters (d = 0.85,
95% CI 0.39–1.29), but not non-responders. Serum BDNF levels
increased more in remitters and responders compared to

































sham-controlled trials of tDCS for Major
Depressive Disorder in Medline database.
Main focus of review on general efficacy
of tDCS. Meta-regression using random
effects model also performed to assess
association between predictor variables
and outcomes.
Adults with MDD enrolled in a
randomised trial receiving
tDCS alone or in combination
with pharmacotherapy.
n = 7 studies.
259 participants
Within-group predictive variable: Meta-regression suggested no
strong evidence of age, gender, baseline depression severity or
treatment-resistant depression on outcomes.
Critically
low
















reduction of 20, 25%













cut of ≤7 in HAMD




















or: Early improvement of all antidepressant
bined predicted response (sensitivity 83%,
OR 19.15 [95% CI 18.4–19.9]) and remission
specificity 42%, DOR 15.70 [95% CI 14.9–16.5]) at
igh sensitivity and low-to-moderate specificity.
specificities felt to be similar between
except SSRIs, where early improvement may have
value.
ent of placebo group predicted response
specificity 67%, DOR 27.29 [95% CI 25.0–29.7])
ensitivity 76%, specificity 61%, DOR 15.82 [95% CI
dpoint. This suggests differential response
and pharmacotherapy arms for response but not
redictive variable: Patients with early
ere more likely to achieve response (pooled
.000) or remission (OR = 6.38, p b .000)
se without early improvement.
eline severity on response (p = .744) and




[Prognostic factor: a variablewhichmoderates response but does not interactwith treatm compared to placebo; Effectmodifier: a variablewhichmoderates
response and interacts with treatment; Within-group predictive variable: a variable whi
a [E] = Efficacy, [T] = Tolerability, [A] = Acceptability.
b Rating determined using AMSTAR-2 instrument.hods Population Interpretation
ch of randomised, double-blind,
ebo-controlled studies of
epressant medications vs placebo or
her antidepressant in MDD in
line, EMBASE, Web of Science,
HL, PsycINFO, CENTRAL and
erous clinical trials databases.
itivity, specificity, positive and
tive predictive values, false positives
negatives and diagnostic odds ratio
calculated for all antidepressants,
ell as separated by class and
idual drug. Meta-analysis and
a-regression calculated odds ratios to
the association between early
rovement and baseline severity and
omes.
Adults with acute MDD
according to DSM-IV,
DSM-III-R or DSM-III receiving
antidepressant medication in
RCT setting.




















OR = 8.37, p b
compared to tho
The effect of bas
remission (p =
of odds ratios fo
ent; Specific predictor: a variablewhich affects outcome differentially for active intervention
ch predicts within-group effects but is not compared across treatment arms or placebo].
Table 5
Reviews of individual predictor variables lacking appropriate quality, transparency or rigour (classified as “level 3” evidence).
Author & year Intervention Variable(s) of interest Outcomea Population Sample Interpretation Reason
classified as
level 3
Chen et al., 2018 Amitriptyline or
placebo





Adults enrolled in a randomised-trial
setting. 80% had depression, other
diagnoses included irritable bowel










Specific predictor Odds ratio for sexual dysfunction
for male patients was 2.6 (χ2 = 6.03, p b .025) and
0.37 (χ2 = 4.27, p b .05) for female patients.
Within-group predictive variable
Positive linear correlation between sexual
dysfunction and insomnia (r2 = 0.996, F = 231.5,
p b .05) and a biphasic correlation with somnolence
(r2 = 0.9342, F = 56.8, p b .01) and nausea
(r2 = 0.9107, F = 30.6, p b .05).
No correlation with all other adverse effects










Sex, race, cohabitation status,




Adults with a diagnosis of MDD or
post-partum depression enrolled in a
randomised trial in an outpatient
setting.






Pooled analysis predictive variable
Percentage of patients of minority racial status
predicted higher dropout (Freeman-Turkey esti-
mate: 0.432, 95% CI: 0.04, 0.82).
Percentage of patients with comorbid personality
disorder was strongly predictive of higher dropout,
but only provided in approximately one quarter of
treatment conditions (Freeman-Turkey estimate:
0.976, 95% CI: 0.56, 1.39).









13 characteristics, including type
of depression, sociodemographic








Participants with an established
depressive disorder (including
dysthymia) enrolled in a randomised
trial.




Pharmacotherapy more effective than
psychotherapy in patients with dysthymia
(g = −0.28; 95% CI: −0.53-0.04), postnatal
depression and infertile women, however. No
strong association with other predictors, although
analyses generally lacked statistical power.
Combination more effective than pharmacotherapy
in older patients, chronic depression,
treatment-resistant depression, impaired cognitive
function and comorbid borderline personality
disorder. No strong association with other
predictors, but analyses generally lacked power.
Combination more effective than psychotherapy in
chronic depression. No strong association with
other predictors, but analyses generally lacked
power.

















Adults enrolled in a randomised
controlled trial diagnosed with major
depressive disorder (including
dysthymia) or with depressive
symptoms above cut-off on a rating
scale.
n = 53 studies
4740
participants
Pooled analysis predictive variable
No evidence that baseline HAM-D severity was a
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Adults enrolled in a randomised
controlled trial diagnosed with major
depressive disorder (including
dysthymia) or with depressive
symptoms above cut-off on a rating
scale.




Chara ristics were limited to those with sufficient
powe r comparisons to find a clinically significant
effect e. Three characteristics were found to be
associ d with response; CBT more effective than
other ychotherapies in older adults (g = 0.29), in
patien with comorbid alcohol problems
(g = 1), and in university students (g = 0.46).
Howe r, authors advise caution due to inclusion of
studie ith high risk of bias.
Heterogeneous
population




Sex, age, education, co-morbid
anxiety, depression severity
Deterioration, defined as




Adults with a diagnosis of depression in
an acute depressive episode.
n = 18 RCTs
2079
participants
Withi group predictive variable
Lower moderate/high education level was a
predic r of within-group deterioration (low
educa n RR: 1.72, 95% CI: 0.53–5.61,
mode e/high education RR: 0.39, 95% CI:
0.22– 8). No strong evidence that other variables
















Patients with a diagnosis of a depressive
disorder as per DSM or ICD criteria.
n = 8 studies
212
participants
Poole nalysis predictive variable
Highe asal cortisol predicted poor within-group
respo to treatment (mean ES = 0.264, 95% CI




















Adults with unipolar depressive disorder
enrolled in trial setting.
n = 70 studies
2426
participants
Withi group predictive variable
Perce ge of men enrolled in study predicted
worse eatment effect (change coefficient:
−0.01 , 95% CI: 0.019, 0.001). Other variables
were t strongly associated with outcome.
















Adults with a diagnosis of depressive
disorder in an RCT setting.
n = 10 studies
2705
participants
Poole nalysis predictive variable
Male der (RR 1.08, CI 1.03–1.13), lower
educa nal level (primary education: RR 1.26, CI
1.14– 9), older age (RR 0.94, CI 0.87–1.02) and
como d anxiety (RR 1.18, 95% CI 1.01–1.38)
predic d treatment dropout, but effect sizes were
small
Baseli depression severity, employment status











(physical abuse, sexual abuse,








Participants with a diagnosis of
depressive disorder in population or
community samples.




In pha acological and combination treatments,
maltr ment history predicted poorer outcome
(odds tio = 1.26, 95% CI = 1.01–1.56) and (odds
ratio 1.90, 95% CI = 1.40–2.58) respectively. In
psych erapy treatment, maltreatment history not
strong associated with poorer outcome (odds
ratio 1.12, 95% CI = 0.68–1.85). However, no
direct atistical analysis between different
treatm ts.
Poole nalysis predictive variable
Indivi als with a history of maltreatment more
likely ve poor within-group treatment outcome






































































Adults diagnosed with depression as
defined or with symptoms scored on
standardised scale. Excluded studies
with a large number of older adults
(N65), postnatal or atypical depression.






Pooled analysis predictive variable
Both age (coefficient − 0.02, CI: −0.04;0.00) and
gender (coefficient 0.00, CI:-0.01;0.01) not strongly













Adults in a depressive episode as
determined by clinician-rated
standardised measure.
n = 35 articles
1908
participants
Pooled analysis predictive variable
No strong differences identified between
responders and non-responders for baseline
TNF-alpha (effect size: 0.08, 95% CI: 0.34, 0.17), CRP
(effect size: 0.03, 95% CI: 0.22, 0.16), and IL-6 (effect















remission or change in




Adults over the age of 60 with a
diagnosis of major depression according
to DSM/ICD enrolled in a randomised
trial.
n = 67 studies Effect modifier
Age, baseline depression and anxiety and physical
comorbidity appeared to have a small moderator
effect in a subgroup analysis when interventions
grouped by biological, psychosocial or both.
Pooled analysis predictive variable
65 predictor variables reported in individual
studies, of which seven were reported in over three
studies. These were age, baseline severity, early
improvement, current episode duration, baseline
anxiety, physical comorbidity and set shifting in the
trail making test. In meta-analysis, only baseline
anxiety, baseline depression and the trail-making
test were strong predictors of within-group
treatment response.











Human subjects receiving a treatment
modality for depressive illness.
n = 76 articles Pooled analysis predictive variable
Overall meta-analytic sensitivity was 0.72
(CI = 0.67–0.76), specificity was 0.68
(CI = 0.63–0.73), and log(diagnostic odds ratio)
was 1.89 (CI = 1.56–2.21), corresponding to area
under the curve of 0.76 (CI = 0.71–0.80).
Effect modifier
Meta-analytic subgroup analysis found no strong
difference for predictive utility between treatment
groups. Diagnostic odds ratio for rTMS (2.19 CI
1.22;3.15), pharmacotherapy (1.89 CI 1.53;2.26)
and other treatment modalities (1.37 CI 0.26;2.49).
Heterogeneous
interventions
[Prognostic factor: a variablewhichmoderates response but does not interact with treatment; Specific predictor: a variablewhich affects outcome differentially for active intervention compared to placebo; Effectmodifier: a variablewhichmoderates
response and interactswith treatment;Within-group predictive variable: a variablewhich predictswithin-group effects but is not compared across treatment arms or placebo; Pooled analysis predictive variable: a variableswhich predicts response in
a pooled grouping of multiple treatment interventions and/or placebo].
a Efficacy = [E], Tolerability = [T], Acceptability = [A].
Table 6
Included reviews of clinical prediction models.
Author &
year





































once a day for over





















or in combination with
supportive
pharmacotherapy.













as 50% reduction in
HDRS from
baseline to week 6
and remission,
defined as HDRS











































(Geschwind t al., 2011)
focused on a clinical
prediction model.
In a sample of 49
depressed patients, the
association between
change in positive and
negative emotions and
severity of depression
at week 6 was
examined.
Early change in HDRS
combined with early






= 6.24, p b 0.05;
remission chi-square =


















































































































Only 4 of 20 studies
evaluated model
performance in a





























































































































































































































and remission, but this











study of Genecept Assay























⁎ [E] = Efficacy, [T] = Tolerability, [A] = Acceptability



































No primary diagnosis of unipolar 
depression: 382
No treatment intervenon: 350
Not adults: 79
Not human: 32









Summary of case reports: 1
PREDICTOR VARIABLES










Key: Level 0 = database given but no date range; 
Level 1 = database & date range; Level 2a = 
PRISMA diagram included; 2b = crical analysis 
with standardised tool; 2(a+b) = PRISMA & 















Full-text arcles assessed 
for eligibility
(n = 205)
Fig. 1. PRISMA flow diagram of meta-review process
